COMMUNIQUÉS West-GlobeNewswire

LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook
05/11/2026
SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third [...]
Arcoma AB (publ) offentliggör att Eiffel Investment Group passerat 10 procent av aktierna och rösterna.
05/11/2026
PRESSRELEASE 2026-11-05 Arcoma AB (publ) offentliggör att Eiffel Investment Group passerat 10 procent av aktierna och rösterna. Arcoma AB (publ) ("Arcoma") har mottagit information från Eiffel Investment Group om att de [...]
2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint
05/11/2026
BEIJING, Nov. 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that results from [...]
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting
05/11/2026
Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours VANCOUVER, British Columbia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS [...]
Resalis Therapeutics Announces First-in-Human Data for RES-010 Demonstrating Safety and Tolerability with Early Weight Loss Signals
05/11/2026
The completed Phase 1a study data in healthy volunteers showed early signs of pharmacodynamic activity supporting further clinical evaluation of RES-010 The Phase 1b study in healthy overweight and moderately obese [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026 , Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
CurePSP Names First Recipients of Biomarker Accelerator Program, Awarding Its Largest Research Grants to Date
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CurePSP has awarded more than $1.4 million through its Biomarker Accelerator Program to three researchers working to find reliable biomarkers for progressive supranuclear [...]
Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease
05/11/2026
Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up [...]
ArrayPatch boucle un tour de financement d’amorçage sursouscrit de 3,2 millions d’euros pour faire progresser ses traitements par micro-aiguilles de nouvelle génération
05/11/2026
CORK, Irlande, 05 nov. 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (« ArrayPatch »), une société de biotechnologie développant des traitements novateurs à base de micro-aiguilles, a annoncé aujourd’hui la clôture réussie de [...]
ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics
05/11/2026
CORK, Ireland, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, today announced the successful completion of the second close of [...]
Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms
05/11/2026
Series A financing co-led by Sofinnova Partners and RA Capital alongside founding investor Oxford Science Enterprises with support from Cancer Research Horizons and the University of Oxford, bringing together a world- [...]
Ethris Reports Positive Topline Phase 2a Data for Nasal mRNA Candidate ETH47 in Asthma Patients Challenged with Rhinovirus
05/11/2026
40-fold lower virus load compared to placebo on Day 2, at the peak of viral replication Exposure-response relationship observed, with greater interferon lambda (IFNλ) exposure associated with greater antiviral and [...]
9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
05/11/2026
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7 [...]
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
05/11/2026
$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M- [...]
Interim report 9M 2026
05/11/2026
Strong Q3 sales leading to 9M at 7% organic sales growth and adj. EBITDA margin of 37.9%. 2026 outlook confirmed: 7-8% organic sales growth and adj. EBITDA margin at the higher end of the 37-38% range. Ester Baiget, [...]
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
05/11/2026
Egetis Therapeutics’ lead asset, EMCITATE ® , is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 [...]
Siemens Healthineers to Rebrand In Vitro Diagnostics Business as Olyrian Diagnostics
05/11/2026
Siemens Healthineers announced today it has initiated the carve-out process for its in vitro diagnostics business Tarrytown, New York, USA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The company is preparing its Diagnostics [...]
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
05/11/2026
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update Ongoing negotiations with different parties towards securing a partnership or financing for the development of varoglutamstat in [...]
Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook
05/11/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook Männedorf, Switzerland, November [...]

Pages